APA (7th ed.) Citation

Orito, Y., Otani, N., Matsumoto, Y., Fujimoto, K., Oshima, N., Maas, B. M., . . . Uemura, N. (2022). A phase I study to evaluate safety, pharmacokinetics, and pharmacodynamics of respiratory syncytial virus neutralizing monoclonal antibody MK‐1654 in healthy Japanese adults. Clinical and Translational Science, 15(7), 1753-1763. https://doi.org/10.1111/cts.13290

Chicago Style (17th ed.) Citation

Orito, Yuji, et al. "A Phase I Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of Respiratory Syncytial Virus Neutralizing Monoclonal Antibody MK‐1654 in Healthy Japanese Adults." Clinical and Translational Science 15, no. 7 (2022): 1753-1763. https://doi.org/10.1111/cts.13290.

MLA (9th ed.) Citation

Orito, Yuji, et al. "A Phase I Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of Respiratory Syncytial Virus Neutralizing Monoclonal Antibody MK‐1654 in Healthy Japanese Adults." Clinical and Translational Science, vol. 15, no. 7, 2022, pp. 1753-1763, https://doi.org/10.1111/cts.13290.